CUE BIOPHARMA INC's ticker is CUE and the CUSIP is 22978P106. A total of 91 filers reported holding CUE BIOPHARMA INC in Q3 2021. The put-call ratio across all filers is 0.43 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $98,915 | -16.3% | 27,100 | -18.1% | 0.00% | – |
| Q1 2023 | $118,167 | -61.9% | 33,100 | -69.6% | 0.00% | -100.0% |
| Q4 2022 | $310,365 | -24.1% | 108,900 | -40.6% | 0.00% | 0.0% |
| Q3 2022 | $409,000 | -23.3% | 183,300 | -14.4% | 0.00% | -50.0% |
| Q2 2022 | $533,000 | -46.9% | 214,100 | +4.2% | 0.00% | -33.3% |
| Q1 2022 | $1,003,000 | -61.0% | 205,500 | -9.6% | 0.00% | -50.0% |
| Q4 2021 | $2,570,000 | -12.7% | 227,200 | +12.5% | 0.01% | -25.0% |
| Q3 2021 | $2,943,000 | -15.2% | 202,000 | -32.2% | 0.01% | -11.1% |
| Q2 2021 | $3,472,000 | -22.3% | 298,000 | -18.6% | 0.01% | -25.0% |
| Q1 2021 | $4,466,000 | +1.8% | 366,100 | +4.4% | 0.01% | 0.0% |
| Q4 2020 | $4,387,000 | -0.7% | 350,700 | +19.5% | 0.01% | -7.7% |
| Q3 2020 | $4,416,000 | +30.9% | 293,400 | +113.2% | 0.01% | +30.0% |
| Q2 2020 | $3,373,000 | +2148.7% | 137,600 | +1198.1% | 0.01% | +900.0% |
| Q1 2020 | $150,000 | – | 10,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 1,545,573 | $3,447,000 | 1.85% |
| P.A.W. CAPITAL CORP | 200,000 | $446,000 | 0.67% |
| SANDERS MORRIS HARRIS LLC | 848,048 | $2,020,000 | 0.50% |
| Monaco Asset Management SAM | 458,851 | $1,023,000 | 0.39% |
| Bleichroeder LP | 555,000 | $1,238,000 | 0.26% |
| APOGEM CAPITAL LLC | 110,614 | $247,000 | 0.25% |
| Slate Path Capital LP | 1,483,619 | $3,308,000 | 0.22% |
| Voss Capital, LLC | 200,000 | $446,000 | 0.13% |
| Robertson Stephens Wealth Management, LLC | 478,500 | $1,067,000 | 0.11% |
| CARLSON CAPITAL L P | 535,000 | $1,193,000 | 0.09% |